Public Company

Unity Biotechnology

About

Unity Biotechnology is a biotechnology and frontier medicine company with a mission to develop a new class of therapeutics to reduce, eliminate, or reverse aging diseases. Their mission to extend lifespan without the burden of disease starts with an initial focus to eliminate or better control senescent cells. Thereby providing direct transformative change in age related ophthalmologic and neurologic diseases with specific therapy including diabetic macular edema and age related macular degeneration.

Overview

Founded 2011
Type Public
Location San Francisco, California, USA

Stock

UBX $4.46 3.36% $0.15

Latest News

UNITY Biotechnology Reports Granting of New Employment Inducement Award Jan 18, 2023 GlobeNewswire Inc. SOUTH SAN FRANCISCO, Calif., Jan. 18, 2023 (GLOBE NEWSWIRE) -- UNITY Biotechnology, Inc. (“UNITY”) [NASDAQ: UBX], a biotechnology company developing therapeutics to slow, halt, or...
UNITY Biotechnology to Host Program Update on BEHOLD, the Phase 2 Clinical Trial of UBX1325 in Patients with Diabetic Macular Edema Oct 31, 2022 GlobeNewswire Inc. Program Update with retinal expert Arshad M. Khanani, M.D., M.A., FASRS, to be held on Tuesday, November 1 at 5:00 a.m. PT/8:00 a.m. ET Program...
All You Need to Know About UNITY Biotechnology, Inc. (UBX) Rating Upgrade to Strong Buy Oct 10, 2022 Zacks Investment Research UNITY Biotechnology, Inc. (UBX) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive...
Bears are Losing Control Over UNITY Biotechnology, Inc. (UBX), Here's Why It's a 'Buy' Now Aug 30, 2022 Zacks Investment Research UNITY Biotechnology, Inc. (UBX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition...
This Biotechnology Stock Tumbled 37%; Here Are 70 Biggest Movers From Yesterday Aug 19, 2022 Benzinga Gainers Bright Minds Biosciences Inc. (NASDAQ: DRUG) shares climbed 135.9% to close at $2.17 on Thursday. Plus Therapeutics, Inc. (NASDAQ: PSTV) shares climbed 53.9% to...